MediciNova (NASDAQ:MNOV) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV) in a research note published on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Stock Performance

Shares of MNOV stock opened at $1.95 on Friday. The company has a market capitalization of $95.64 million, a PE ratio of -11.47 and a beta of 0.75. MediciNova has a 52-week low of $1.12 and a 52-week high of $2.16. The business’s fifty day moving average is $1.59 and its 200 day moving average is $1.46.

MediciNova (NASDAQ:MNOV) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, sell-side analysts forecast that MediciNova will post -0.23 EPS for the current fiscal year.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.